(March 26, 2019) The NCCN, or the National Comprehensive Cancer Network, recently updated its clinical guidelines for the treatment of ovarian cancers. The guidelines, a summary of which can be found here, have been updated after several studies were completed and the FDA approved several new drugs. The new guidelines address topics such as PARP inhibitor maintenance therapy, platinum sensitive vs platinum resistant agents, and PARP inhibitor criteria for patients.
Please note that, although the article is free, you are required to register with the website.
